LINC00174 Suppresses Non-Small Cell Lung Cancer Progression by Up-Regulating LATS2 via Sponging miR-31-5p. 2022

Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
Department of Operation, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.

Dysregulation of long non-coding RNAs (lncRNAs) is associated with the progression of non-small cell lung cancer (NSCLC). This study aimed to investigate the role of long intergenic non-protein coding RNA 174 (LINC00174) in NSCLC. In this experimental study, LINC00174 expression in NSCLC tissues and cell lines was investigated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Besides, cell counting kit-8 (CCK-8), 5-bromo-2'-deoxyuridine (BrdU). Transwell and Flow Cytometry assays were applied to detect the regulatory function of LINC00174 on the growth, migration and apoptosis of NSCLC cells. Bioinformatics analysis, dual luciferase reporter gene assay and RNA immunoprecipitation (RIP) assay predicted and verified the targeting relationship between LINC00174 and miR-31-5p, and between miR-31-5p and the 3´-untranslated region (3´UTR) of large tumor suppressor kinase 2 (LATS2), respectively. Western blotting was performed to detect the regulatory function of LINC00174 and miR-31-5p on LATS2 protein expression. Compared with that in normal lung tissues, LINC00174 expression in NSCLC tissues and cell lines was reduced. LINC00174 expression was negatively associated with the TNM stage of the patients. Functional experiments showed that LINC00174 overexpression inhibited NSCLC cell multiplication and migration, and induced apoptosis. Furthermore, LINC00174 targeted miR-31-5p and repressed its expression. Additionally, LINC00174 upregulated LATS2 expression through competitively binding to miR-31-5p. LINC00174, as a competitive endogenous RNA, elevates LATS2 expression by adsorbing miR-31-5p, thereby inhibiting the viability and migration of NSCLC cells, and promoting apoptosis.

UI MeSH Term Description Entries

Related Publications

Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
July 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
January 2022, Cancer biomarkers : section A of Disease markers,
Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
October 2020, European review for medical and pharmacological sciences,
Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
November 2019, European review for medical and pharmacological sciences,
Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
March 2022, Journal of thoracic disease,
Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
January 2022, Disease markers,
Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
October 2023, Thoracic cancer,
Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
January 2020, Cancer cell international,
Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
June 2024, Cellular and molecular biology (Noisy-le-Grand, France),
Xueling Cheng, and Mali Sha, and Wenjin Jiang, and Linjing Chen, and Meihua Song
January 2019, Journal of Cancer,
Copied contents to your clipboard!